---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017507"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:05:18.904469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q3 cash $49.4M; uproleselan Phase 3 topline by Q2 2024; NDA filing by end 2024

## Summary
- Cash and cash equivalents $49.4M as of Sep 30, 2023; no revenue reported (pre-revenue biotech).
- Pivotal Phase 3 uproleselan topline results on track for end of Q2 2024; NDA filing expected by end 2024.
- Phase 1a GMI-1687 initial results expected by end of Q1 2024 as potential sickle cell disease treatment.
- R&D expenses $5.3M (up from $4.9M) driven by GMI-1687 trial; G&A expenses $4.5M (up from $3.8M).
- Updated uproleselan data in secondary AML to be presented at ASH December 2023.

## SEC filing metadata
- accession: 0001558370-23-017507
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/glyc-20231103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017507
- JSON: https://secwatch.observer/filing/0001558370-23-017507.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017507.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.